PPARA and liver dysplastic nodule: Moreover, PPAR-α agonist fenofibrate has been proven to prevent DN and reduce urinary albumin in diabetic patients (26, 27) and in diabetic mice (29–32), which is independent of the effect on lipid-lowering.